Epinephrine self-injectable - kaleo

Drug Profile

Epinephrine self-injectable - kaleo

Alternative Names: Allerject; Auvi-Q; e-cue

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intelliject
  • Developer kaleo; Sanofi
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaphylaxis; Hypersensitivity

Most Recent Events

  • 27 Jul 2017 Epinephrine auto-injector receives priority review status for Anaphylaxis in USA
  • 27 Jul 2017 Kaléo files sNDA for epinephrine auto-injector for the treatment of Anaphylaxis in USA before July 2017
  • 23 Feb 2016 Sanofi and kaleo will terminate the license and development agreement by the end of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top